Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 387

1.

Polygenic and environmental influences on the course of African Americans' alcohol use from early adolescence through young adulthood.

Rabinowitz JA, Musci RJ, Reboussin B, Milam AJ, Benke KS, Uhl GR, Sisto DY, Ialongo NS, Maher BS.

Dev Psychopathol. 2019 Jul 1:1-16. doi: 10.1017/S0954579419000701. [Epub ahead of print]

PMID:
31256767
2.

Dopamine compartmentalization, selective dopaminergic vulnerabilities in Parkinson's disease and therapeutic opportunities.

Uhl GR.

Ann Clin Transl Neurol. 2019 Jan 8;6(2):406-415. doi: 10.1002/acn3.707. eCollection 2019 Feb. Review.

3.

Repeated methamphetamine treatment increases spine density in the nucleus accumbens of serotonin transporter knockout mice.

Kasahara Y, Sakakibara Y, Hiratsuka T, Moriya Y, Lesch KP, Hall FS, Uhl GR, Sora I.

Neuropsychopharmacol Rep. 2019 Jun;39(2):130-133. doi: 10.1002/npr2.12049. Epub 2019 Feb 4.

4.

PTPRD: neurobiology, genetics, and initial pharmacology of a pleiotropic contributor to brain phenotypes.

Uhl GR, Martinez MJ.

Ann N Y Acad Sci. 2019 Jan 15. doi: 10.1111/nyas.14002. [Epub ahead of print] Review.

PMID:
30648269
5.

The neurobiology of addiction.

Uhl GR, Koob GF, Cable J.

Ann N Y Acad Sci. 2019 Jan 15. doi: 10.1111/nyas.13989. [Epub ahead of print]

PMID:
30644552
6.

Brain hyperserotonemia causes autism-relevant social deficits in mice.

Tanaka M, Sato A, Kasai S, Hagino Y, Kotajima-Murakami H, Kashii H, Takamatsu Y, Nishito Y, Inagaki M, Mizuguchi M, Hall FS, Uhl GR, Murphy D, Sora I, Ikeda K.

Mol Autism. 2018 Nov 26;9:60. doi: 10.1186/s13229-018-0243-3. eCollection 2018.

7.

Cocaine reward is reduced by decreased expression of receptor-type protein tyrosine phosphatase D (PTPRD) and by a novel PTPRD antagonist.

Uhl GR, Martinez MJ, Paik P, Sulima A, Bi GH, Iyer MR, Gardner E, Rice KC, Xi ZX.

Proc Natl Acad Sci U S A. 2018 Nov 6;115(45):11597-11602. doi: 10.1073/pnas.1720446115. Epub 2018 Oct 22.

8.

Larger Numbers of Glial and Neuronal Cells in the Periaqueductal Gray Matter of μ-Opioid Receptor Knockout Mice.

Sasaki K, Hall FS, Uhl GR, Sora I.

Front Psychiatry. 2018 Sep 19;9:441. doi: 10.3389/fpsyt.2018.00441. eCollection 2018.

9.

The interplay between externalizing disorders polygenic risk scores and contextual factors on the development of marijuana use disorders.

Rabinowitz JA, Musci RJ, Milam AJ, Benke K, Uhl GR, Sisto DY, Ialongo NS, Maher BS.

Drug Alcohol Depend. 2018 Oct 1;191:365-373. doi: 10.1016/j.drugalcdep.2018.07.016. Epub 2018 Aug 25.

PMID:
30195949
10.

Reward-enhancing effect of methylphenidate is abolished in dopamine transporter knockout mice: A model of attention-deficit/hyperactivity disorder.

Ide S, Ikekubo Y, Hua J, Takamatsu Y, Uhl GR, Sora I, Ikeda K.

Neuropsychopharmacol Rep. 2018 Sep;38(3):149-153. doi: 10.1002/npr2.12020. Epub 2018 Jun 29.

11.

Tetrabenazine, a vesicular monoamine transporter-2 inhibitor, attenuates morphine-induced hyperlocomotion in mice through alteration of dopamine and 5-hydroxytryptamine turnover in the cerebral cortex.

Kitanaka N, Kitanaka J, Hall FS, Kandori T, Murakami A, Muratani K, Nakano T, Uhl GR, Takemura M.

Pharmacol Biochem Behav. 2018 Sep;172:9-16. doi: 10.1016/j.pbb.2018.07.002. Epub 2018 Jul 12.

PMID:
30017858
12.

The Role of Cell Adhesion Molecule Genes Regulating Neuroplasticity in Addiction.

Muskiewicz DE, Uhl GR, Hall FS.

Neural Plast. 2018 Feb 20;2018:9803764. doi: 10.1155/2018/9803764. eCollection 2018. Review.

13.

Psychotomimetic-like behavioral effects of memantine in the mouse.

Kitanaka N, Kitanaka J, Hall FS, Kubota Y, Mimura Y, Ogura S, Okada Y, Uhl GR, Takemura M.

Biomed Pharmacother. 2018 Apr;100:116-123. doi: 10.1016/j.biopha.2018.01.160. Epub 2018 Feb 8.

PMID:
29427922
14.

Distinct Roles of Opioid and Dopamine Systems in Lateral Hypothalamic Intracranial Self-Stimulation.

Ide S, Takahashi T, Takamatsu Y, Uhl GR, Niki H, Sora I, Ikeda K.

Int J Neuropsychopharmacol. 2017 May 1;20(5):403-409. doi: 10.1093/ijnp/pyw113.

15.

Cadherin 13: human cis-regulation and selectively-altered addiction phenotypes and cerebral cortical dopamine in knockout mice.

Drgonova J, Walther D, Hartstein GL, Bukhari MO, Baumann MH, Katz J, Hall FS, Arnold ER, Flax S, Riley A, Rivero-Martin O, Lesch KP, Troncoso J, Ranscht B, Uhl GR.

Mol Med. 2016 Oct;22:537-547. doi: 10.2119/molmed.2015.00170. Epub 2016 Aug 18.

16.
17.

Brain Histamine N-Methyltransferase As a Possible Target of Treatment for Methamphetamine Overdose.

Kitanaka J, Kitanaka N, Hall FS, Uhl GR, Takemura M.

Drug Target Insights. 2016 Mar 2;10:1-7. doi: 10.4137/DTI.S38342. eCollection 2016. Review.

18.

Pretreatment or Posttreatment with Aripiprazole Attenuates Methamphetamine-induced Stereotyped Behavior in Mice.

Kitanaka N, Kitanaka J, Hall FS, Kayama M, Sugimori H, Uhl GR, Takemura M.

J Exp Neurosci. 2015 Sep 10;9(Suppl 1):1-10. doi: 10.4137/JEN.S27733. eCollection 2015.

19.

Mouse Model for Protein Tyrosine Phosphatase D (PTPRD) Associations with Restless Leg Syndrome or Willis-Ekbom Disease and Addiction: Reduced Expression Alters Locomotion, Sleep Behaviors and Cocaine-Conditioned Place Preference.

Drgonova J, Walther D, Wang KJ, Hartstein GL, Lochte B, Troncoso J, Uetani N, Iwakura Y, Uhl GR.

Mol Med. 2015 Nov;21(1):717-725. doi: 10.2119/molmed.2015.00017. Epub 2015 Jul 14.

20.

Altered CSMD1 Expression Alters Cocaine-Conditioned Place Preference: Mutual Support for a Complex Locus from Human and Mouse Models.

Drgonova J, Walther D, Singhal S, Johnson K, Kessler B, Troncoso J, Uhl GR.

PLoS One. 2015 Jul 14;10(7):e0120908. doi: 10.1371/journal.pone.0120908. eCollection 2015.

21.

Human cell adhesion molecules: annotated functional subtypes and overrepresentation of addiction-associated genes.

Zhong X, Drgonova J, Li CY, Uhl GR.

Ann N Y Acad Sci. 2015 Sep;1349:83-95. doi: 10.1111/nyas.12776. Epub 2015 May 18. Review.

22.

Memory impairment and reduced exploratory behavior in mice after administration of systemic morphine.

Kitanaka J, Kitanaka N, Hall FS, Fujii M, Goto A, Kanda Y, Koizumi A, Kuroiwa H, Mibayashi S, Muranishi Y, Otaki S, Sumikawa M, Tanaka K, Nishiyama N, Uhl GR, Takemura M.

J Exp Neurosci. 2015 May 11;9:27-35. doi: 10.4137/JEN.S25057. eCollection 2015.

23.

Region-specific dendritic spine loss of pyramidal neurons in dopamine transporter knockout mice.

Kasahara Y, Arime Y, Hall FS, Uhl GR, Sora I.

Curr Mol Med. 2015;15(3):237-44.

PMID:
25817859
24.

Improvement of learning and increase in dopamine level in the frontal cortex by methylphenidate in mice lacking dopamine transporter.

Takamatsu Y, Hagino Y, Sato A, Takahashi T, Nagasawa SY, Kubo Y, Mizuguchi M, Uhl GR, Sora I, Ikeda K.

Curr Mol Med. 2015;15(3):245-52.

25.

Methylone-induced hyperthermia and lethal toxicity: role of the dopamine and serotonin transporters.

Piao YS, Hall FS, Moriya Y, Ito M, Ohara A, Kikura-Hanajiri R, Goda Y, Lesch KP, Murphy DL, Uhl GR, Sora I.

Behav Pharmacol. 2015 Jun;26(4):345-52. doi: 10.1097/FBP.0000000000000135.

PMID:
25794333
26.

Functional consequences of 17q21.31/WNT3-WNT9B amplification in hPSCs with respect to neural differentiation.

Lee CT, Bendriem RM, Kindberg AA, Worden LT, Williams MP, Drgon T, Mallon BS, Harvey BK, Richie CT, Hamilton RS, Chen J, Errico SL, Tsai SY, Uhl GR, Freed WJ.

Cell Rep. 2015 Feb 3;10(4):616-32. doi: 10.1016/j.celrep.2014.12.050. Epub 2015 Jan 29.

27.

Serotonin/dopamine interactions in a hyperactive mouse: reduced serotonin receptor 1B activity reverses effects of dopamine transporter knockout.

Hall FS, Sora I, Hen R, Uhl GR.

PLoS One. 2014 Dec 16;9(12):e115009. doi: 10.1371/journal.pone.0115009. eCollection 2014.

28.

Attenuated methamphetamine-induced locomotor sensitization in serotonin transporter knockout mice is restored by serotonin 1B receptor antagonist treatment.

Igari M, Shen HW, Hagino Y, Fukushima S, Kasahara Y, Lesch KP, Murphy DL, Hall FS, Uhl GR, Ikeda K, Yaegashi N, Sora I.

Behav Pharmacol. 2015 Feb;26(1-2):167-79. doi: 10.1097/FBP.0000000000000120.

PMID:
25485646
29.

Sex differences in the effects of adolescent social deprivation on alcohol consumption in μ-opioid receptor knockout mice.

Moriya Y, Kasahara Y, Hall FS, Sakakibara Y, Uhl GR, Tomita H, Sora I.

Psychopharmacology (Berl). 2015 Apr;232(8):1471-82. doi: 10.1007/s00213-014-3784-y. Epub 2014 Nov 4.

PMID:
25363463
30.

Preface for Addiction Reviews.

Uhl GR.

Ann N Y Acad Sci. 2014 Oct;1327:v. doi: 10.1111/nyas.12563. No abstract available.

PMID:
25336391
31.

Specific regions display altered grey matter volume in μ-opioid receptor knockout mice: MRI voxel-based morphometry.

Sasaki K, Sumiyoshi A, Nonaka H, Kasahara Y, Ikeda K, Hall FS, Uhl GR, Watanabe M, Kawashima R, Sora I.

Br J Pharmacol. 2015 Jan;172(2):654-67. doi: 10.1111/bph.12807. Epub 2014 Sep 5.

32.

Developmental alterations in anxiety and cognitive behavior in serotonin transporter mutant mice.

Sakakibara Y, Kasahara Y, Hall FS, Lesch KP, Murphy DL, Uhl GR, Sora I.

Psychopharmacology (Berl). 2014 Oct;231(21):4119-33. doi: 10.1007/s00213-014-3554-x. Epub 2014 Apr 13.

PMID:
24728652
33.

Agmatine attenuates methamphetamine-induced hyperlocomotion and stereotyped behavior in mice.

Kitanaka N, Kitanaka J, Hall FS, Uhl GR, Watabe K, Kubo H, Takahashi H, Tanaka K, Nishiyama N, Takemura M.

Behav Pharmacol. 2014 Apr;25(2):158-65. doi: 10.1097/FBP.0000000000000030.

PMID:
24557322
34.

Cell adhesion molecules: druggable targets for modulating the connectome and brain disorders?

Uhl GR, Drgonova J.

Neuropsychopharmacology. 2014 Jan;39(1):235. doi: 10.1038/npp.2013.240. No abstract available.

35.

Curious cases: Altered dose-response relationships in addiction genetics.

Uhl GR, Drgonova J, Hall FS.

Pharmacol Ther. 2014 Mar;141(3):335-46. doi: 10.1016/j.pharmthera.2013.10.013. Epub 2013 Nov 1. Review.

PMID:
24189489
36.

Reducing aggression and impulsivity through school-based prevention programs: a gene by intervention interaction.

Musci RJ, Bradshaw CP, Maher B, Uhl GR, Kellam SG, Ialongo NS.

Prev Sci. 2014 Dec;15(6):831-40. doi: 10.1007/s11121-013-0441-3. Erratum in: Prev Sci. 2014 Dec;15(6):841.

37.

Involvement of the neutral amino acid transporter SLC6A15 and leucine in obesity-related phenotypes.

Drgonova J, Jacobsson JA, Han JC, Yanovski JA, Fredriksson R, Marcus C, Schiöth HB, Uhl GR.

PLoS One. 2013 Sep 4;8(9):e68245. doi: 10.1371/journal.pone.0068245. eCollection 2013.

38.

Decreased vesicular monoamine transporter 2 (VMAT2) and dopamine transporter (DAT) function in knockout mice affects aging of dopaminergic systems.

Hall FS, Itokawa K, Schmitt A, Moessner R, Sora I, Lesch KP, Uhl GR.

Neuropharmacology. 2014 Jan;76 Pt A:146-55. doi: 10.1016/j.neuropharm.2013.07.031. Epub 2013 Aug 24.

39.

Implications of genome wide association studies for addiction: are our a priori assumptions all wrong?

Hall FS, Drgonova J, Jain S, Uhl GR.

Pharmacol Ther. 2013 Dec;140(3):267-79. doi: 10.1016/j.pharmthera.2013.07.006. Epub 2013 Jul 18. Review.

40.

The selective μ opioid receptor antagonist β-funaltrexamine attenuates methamphetamine-induced stereotypical biting in mice.

Kitanaka J, Kitanaka N, Hall FS, Uhl GR, Fukushima Y, Sawai T, Watabe K, Kubo H, Takahashi H, Tanaka K, Nishiyama N, Tatsuta T, Morita Y, Takemura M.

Brain Res. 2013 Jul 19;1522:88-98. doi: 10.1016/j.brainres.2013.05.027. Epub 2013 May 28.

PMID:
23727404
41.

Biomarkers for smoking cessation.

Bough KJ, Lerman C, Rose JE, McClernon FJ, Kenny PJ, Tyndale RF, David SP, Stein EA, Uhl GR, Conti DV, Green C, Amur S.

Clin Pharmacol Ther. 2013 Jun;93(6):526-38. doi: 10.1038/clpt.2013.57. Epub 2013 Mar 18. Review.

42.

B(0)AT2 (SLC6A15) is localized to neurons and astrocytes, and is involved in mediating the effect of leucine in the brain.

Hägglund MG, Roshanbin S, Löfqvist E, Hellsten SV, Nilsson VC, Todkar A, Zhu Y, Stephansson O, Drgonova J, Uhl GR, Schiöth HB, Fredriksson R.

PLoS One. 2013;8(3):e58651. doi: 10.1371/journal.pone.0058651. Epub 2013 Mar 7.

43.

Altered reward circuitry in the norepinephrine transporter knockout mouse.

Gallagher JJ, Zhang X, Hall FS, Uhl GR, Bearer EL, Jacobs RE.

PLoS One. 2013;8(3):e57597. doi: 10.1371/journal.pone.0057597. Epub 2013 Mar 4. Erratum in: PLoS One. 2013;8(8). doi:10.1371/annotation/76516adc-5541-4941-b4ff-e80d1c4d769f.

44.

An evaluation of the serotonin system and perseverative, compulsive, stereotypical, and hyperactive behaviors in dopamine transporter (DAT) knockout mice.

Fox MA, Panessiti MG, Hall FS, Uhl GR, Murphy DL.

Psychopharmacology (Berl). 2013 Jun;227(4):685-95. doi: 10.1007/s00213-013-2988-x. Epub 2013 Feb 17.

PMID:
23417514
45.

Exclusive expression of VMAT2 in noradrenergic neurons increases viability of homozygous VMAT2 knockout mice.

Ohara A, Kasahara Y, Yamamoto H, Hata H, Kobayashi H, Numachi Y, Miyoshi I, Hall FS, Uhl GR, Ikeda K, Sora I.

Biochem Biophys Res Commun. 2013 Mar 15;432(3):526-32. doi: 10.1016/j.bbrc.2013.02.014. Epub 2013 Feb 11.

PMID:
23410751
46.

Impaired cliff avoidance reaction in dopamine transporter knockout mice.

Yamashita M, Sakakibara Y, Hall FS, Numachi Y, Yoshida S, Kobayashi H, Uchiumi O, Uhl GR, Kasahara Y, Sora I.

Psychopharmacology (Berl). 2013 Jun;227(4):741-9. doi: 10.1007/s00213-013-3009-9. Epub 2013 Feb 9.

PMID:
23397052
47.

Personalized medicine and opioid analgesic prescribing for chronic pain: opportunities and challenges.

Bruehl S, Apkarian AV, Ballantyne JC, Berger A, Borsook D, Chen WG, Farrar JT, Haythornthwaite JA, Horn SD, Iadarola MJ, Inturrisi CE, Lao L, Mackey S, Mao J, Sawczuk A, Uhl GR, Witter J, Woolf CJ, Zubieta JK, Lin Y.

J Pain. 2013 Feb;14(2):103-13. doi: 10.1016/j.jpain.2012.10.016. Review.

48.

Smoking quit success genotype score predicts quit success and distinct patterns of developmental involvement with common addictive substances.

Uhl GR, Walther D, Musci R, Fisher C, Anthony JC, Storr CL, Behm FM, Eaton WW, Ialongo N, Rose JE.

Mol Psychiatry. 2014 Jan;19(1):50-4. doi: 10.1038/mp.2012.155. Epub 2012 Nov 6.

49.

Straub tail reaction in mice treated with σ(1) receptor antagonist in combination with methamphetamine.

Kitanaka J, Kitanaka N, Hall FS, Uhl GR, Tanaka K, Nishiyama N, Takemura M.

Brain Res. 2012 Oct 30;1482:40-6. doi: 10.1016/j.brainres.2012.09.001. Epub 2012 Sep 8.

50.

Serotonergic involvement in the amelioration of behavioral abnormalities in dopamine transporter knockout mice by nicotine.

Uchiumi O, Kasahara Y, Fukui A, Hall FS, Uhl GR, Sora I.

Neuropharmacology. 2013 Jan;64:348-56. doi: 10.1016/j.neuropharm.2012.07.016. Epub 2012 Jul 15.

Supplemental Content

Support Center